Logo image of ANCN

Anchiano Therapeutics Ltd ADR (ANCN) Stock Price, Forecast & Analysis

USA - NASDAQ:ANCN -

4.71
+0.24 (+5.37%)
Last: 3/16/2021, 8:00:01 PM
5.53
+0.82 (+17.41%)
After Hours: 3/16/2021, 8:00:01 PM

ANCN Key Statistics, Chart & Performance

Key Statistics
Market Cap34.95M
Revenue(TTM)N/A
Net Income(TTM)-11.61M
Shares7.42M
Float6.97M
52 Week High10.55
52 Week Low0.56
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.78
PE6.04
Fwd PEN/A
Earnings (Next)03-08 2022-03-08/bmo
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


ANCN short term performance overview.The bars show the price performance of ANCN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300

ANCN long term performance overview.The bars show the price performance of ANCN in the last 1, 2 and 3 years. 1 year 2 years 3 years 200 400 600

The current stock price of ANCN is 4.71 null. In the past month the price decreased by -3.68%. In the past year, price increased by 640.57%.

Anchiano Therapeutics Ltd ADR / ANCN Daily stock chart

ANCN Latest News, Press Relases and Analysis

5 years ago - By: Benzinga - Mentions: HPR BGI RUBY NFE ...
News Image
5 years ago - By: Benzinga - Mentions: ADCT BASI LIFE ENZ ...
News Image
5 years ago - By: InvestorPlace
News Image

About ANCN

Company Profile

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily in Cambridge, MA and Jerusalem, Israel. Anchiano Therapeutics Ltd. is based in CAMBRIDGE.

Company Info

Anchiano Therapeutics Ltd ADR

ONE KENDALL SQUARE BUILDING 400 SUITE 14-105

JERUSALEM L3 9777401

CEO: Dr. Frank Haluska

Phone: 857-259-4622

Anchiano Therapeutics Ltd ADR / ANCN FAQ

What does Anchiano Therapeutics Ltd ADR do?

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily in Cambridge, MA and Jerusalem, Israel. Anchiano Therapeutics Ltd. is based in CAMBRIDGE.


What is the current price of ANCN stock?

The current stock price of ANCN is 4.71 null. The price increased by 5.37% in the last trading session.


Does Anchiano Therapeutics Ltd ADR pay dividends?

ANCN does not pay a dividend.


What is the ChartMill rating of Anchiano Therapeutics Ltd ADR stock?

ANCN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


ANCN Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ANCN. When comparing the yearly performance of all stocks, ANCN is one of the better performing stocks in the market, outperforming 98.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ANCN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ANCN. Both the profitability and financial health of ANCN have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANCN Financial Highlights

Over the last trailing twelve months ANCN reported a non-GAAP Earnings per Share(EPS) of 0.78. The EPS increased by 34.1% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -187.88%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%84.51%
Sales Q2Q%N/A
EPS 1Y (TTM)34.1%
Revenue 1Y (TTM)N/A

ANCN Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y-736.99%
Revenue Next YearN/A

ANCN Ownership

Ownership
Inst Owners0.06%
Ins Owners93.99%
Short Float %N/A
Short RatioN/A